Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.

Seminars in cutaneous medicine and surgery - 1 Dec 2012

Curry Jonathan L, Torres-Cabala Carlos A, Tetzlaff Michael T, Bowman Christopher, Prieto Victor G

Abstract excerpt

Metastatic melanoma (MM) is a deadly skin disease refractory to standard chemotherapy. Despite numerous clinical and pathological parameters derived to guide patient management, clinical outcomes in melanoma patients remain difficult to predict. There is a critical need to delineate the important biomarkers typical of this disease. These biomarkers will ideally illuminate those key biochemical pathways...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Mass Spectrometry
Share to Molecular Diagnostic Techniques

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Paraffin Embedding

Share to Real-Time Polymerase Chain Reaction

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 23174497
DOI: 10.1016/j.sder.2012.07.007

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.PMID 23174497Read ↗

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicineSemantic proximity Read ↗

Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.Semantic proximity Read ↗

The Current State of Molecular Testing in the BRAF-Mutated Melanoma LandscapeSemantic proximity Read ↗

Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.Semantic proximity Read ↗

Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.Semantic proximity Read ↗

Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.Semantic proximity Read ↗

Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.Semantic proximity Read ↗

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.Semantic proximity Read ↗

BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating BiomarkersSemantic proximity Read ↗

The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.Semantic proximity Read ↗

Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant MelanomaSemantic proximity Read ↗

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.